Among the companies with shares expected to actively trade in
Thursday's session are CombiMatrix Corp. (CBMX), Merrimack
Pharmaceuticals Inc. (MACK) and Compuware Corp. (CPWR).
CombiMatrix said billable prenatal-testing volumes more than
doubled in the first quarter from a year earlier, and the
genetic-based testing company said it plans to expand its offerings
to capture market share in the rapidly growing market. Shares
soared 27% to $4.40 premarket.
Merrimack said one cohort of a Phase 2 nonsmall cell lung cancer
study didn't meet its primary endpoint. Shares fell 7.4% to $5.75
premarket.
Compuware said it expects its full-year and fiscal
fourth-quarter results to miss prior expectations as many clients
couldn't finalize budgets and postponed deals into the new fiscal
year. Shares were off 2.7% to $11.70 premarket.
CapLease Inc. (LSE) said it plans to offer 6.5 million shares,
sending the real-estate investment trust's shares down 3.1% to
$5.96 premarket. The company had 75.9 million shares outstanding as
of Feb. 15.
Navidea Biopharmaceuticals Inc. (NAVB) said Lymphoseek met its
primary endpoint in identification of sentinel lymph nodes in a
Phase 3 clinical trial of the cancer-seeking agent. Shares rose
8.2% to $2.76 premarket.
Specialty pharmaceutical company pSivida Corp. (PSDV) said it
signed a funded technology evaluation agreement with a leading
global pharmaceutical company, while will evaluate pSivida's
proprietary Durasert and Tethadur technologies for this
pharmaceutical company's select products in ophthalmology. Shares
rose 11% to $2.50 premarket.
Watchlist:
Greenbrier Cos.'s (GBX) fiscal second-quarter earnings fell 22%
as new railcar deliveries continued to decline. The company
supplies railroad equipment and services.
Healthcare Services Group Inc. (HCSG) said the retroactive
reinstatement of a tax-credit program will boost its earnings for
the first quarter.
Lululemon Athletica inc. (LULU, LLL.T) said its chief product
officer Sheree Waterson will leave the company, as the clothing
retailer addresses quality problems after pulling some of its yoga
pants from the shelves last month for being too see-through.
Mitcham Industries Inc.'s (MIND) fiscal fourth-quarter earnings
fell 66% as the seismic-equipment supplier's equipment-leasing
revenue continued to slump. Results missed analyst
expectations.
Pfizer Inc. (PFE) recalled about 52,000 bottles of
thyroid-disease treatment Levoxyl because of complaints of
uncharacteristic odors in some bottles.
RPM International Inc. (RPM) swung to a fiscal third-quarter
loss as the specialty-chemical company was hit by charges related
to a Department of Justice investigation and a business closure.
However, core earnings rose as revenue climbed, sending results
above Street estimates.
Write to Anna Prior at anna.prior@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires